Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
16.49
+0.97 (6.25%)
At close: Oct 29, 2026, 4:00 PM EDT
15.73
-0.76 (-4.61%)
After-hours: Oct 29, 2026, 7:54 PM EDT
Biohaven Earnings Call Transcripts
Fiscal Year 2024
-
Troriluzole demonstrated a 50%-70% reduction in SCA progression over three years, with significant delays in disease decline and reduced fall risk, meeting all primary and secondary endpoints. The therapy was safe, well-tolerated, and is poised for FDA and EMA submissions, potentially becoming the first approved treatment for SCA.